As of March 31, 2025, the Company had cash, cash equivalents and marketable securities totaling $157.5 million.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics management to meet with Truist
- Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp’s Potential in Treating Friedreich’s Ataxia
- Promising Developments and Financial Strength Support Buy Rating for Larimar Therapeutics
- Larimar Therapeutics should be bought on weakness, says Citi
- Larimar Therapeutics price target raised to $16 from $15 at H.C. Wainwright